Market Overview

Benchmark Reiterates Buy on ICU Medical Following Management Meetings


In a report published Monday, Benchmark Company analyst James Terwilliger reiterated a Buy rating and $69.00 price target on ICU Medical (NASDAQ: ICUI).

In the report, Terwilliger noted, “We were recently marketing with a member of the ICU Medical management team, and we remain comfortable with our 2013 revenue and EPS estimates of $335 million and $2.75, respectively. While we remind investors ICUI had a major push-out in Q1:13 from a major customer, we believe it is positioned for an attractive 2H:13 driven by the Oncology business and a return in core business momentum in the Infusion Therapy business.”

ICU Medical closed on Friday at $58.96.

Latest Ratings for ICUI

Aug 2019DowngradesStrong BuyOutperform
Mar 2019MaintainsStrong BuyStrong Buy
Oct 2017Initiates Coverage OnSector Weight

View More Analyst Ratings for ICUI
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Reiteration Analyst Ratings


Related Articles (ICUI)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Skilled Healthcare Group To Continue Pursuing HUD Insured Loans For Up To $460M On 78 Properties

Balch Hill, Potomac Capital Issue Letter to STEC Board, Urge Exploration of Options Including Possible Sale